Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2 – Dosing initiated in Cohort 2 of the registrational study ; topline single-ascending-dose data expected in the first half of 2027 –